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Abstract
Epidemiologic study designs represent a major challenge for genome-wide association studies. Most
such studiesto datehave selectedcontrols fromthe pool of participants without the diseaseof interest
at the end of the study time. These choices can lead to biased estimates of exposure effects. Using data
from theFramingham Heart Study(Genetic AnalysisWorkshop 16 Problem2), we evaluatetheimpact
on genetic association estimates for designs with control selection based on status at the end of a study
(case exclusion (CE) sampling) to control selection based on incidence density (ID) sampling, when
controls are selected from the pool of participants who are disease-free at the time a case is diagnosed.
Cases are defined as those diagnosed with type 2 diabetes (T2D). We estimated odds ratios for 18
previouslyconfirmedT2Dvariantsusing189casesselectedbyIDsamplingandusing231casesselected
by CEsampling. Wefoundnoneof thesesingle-nucleotidepolymorphismstobesignificantlyassociated
with T2D using either design. Because these empirical analyses were based on a small number of cases
and on single-nucleotide polymorphisms with likely small effect sizes, we supplemented this work with
simulated data sets of 500 cases from each strategies across a variety of allele frequencies and effect
sizes. In our simulated datasets, we show ID sampling to be less biased than CE, although CE shows
apparent increased power due to the upward bias of point estimates. We conclude that ID sampling is
an appropriate option for genome-wide association studies.
Background
The genetic architecture of type 2 diabetes (T2D) appears
to be composed of several genes, each of which has a
modest impact on disease risk. Despite significant
advances in our understanding of the genetic determi-
nants of the monogenic forms of diabetes, the definitive
identification of genes that increase risk of common T2D
in the general population has been far more elusive.
However, a string of recent genome-wide association
studies (GWAS) has given promising clues to additional
genes involved in common T2D risk.
GWAS offer an approach to gene discovery unbiased
with regard to presumed functions or locations in the
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for many GWAS is to form a single pool of potential
controls consisting of subjects who were not cases by the
end of the study period. However, this method has been
shown by Greenland and Thomas [1] and Lubin and
Gail [2] to lead to biased estimates of the rate ratio. This
bias has been termed “case-exclusion bias”.M o r e o v e r ,
differences in the origin of populations of cases and
controls can arise if the two groups are recruited
independently or have different inclusion criteria, and
the presence of population stratification can lead to
greater than nominal type I error rate.
Another method of control selection, termed “incidence
density sampling”, uses subjects who survived to the
time of case occurrence to make a pool of potential
controls for each case. The pool of potential controls
may include subjects who later become cases and
subjects who develop other diseases. This nested case-
control design can be a very efficient approach to obtain
unbiased estimates of relative risks associated with
genetic variants.
In this study, we use the GWAS data from the
Framingham Heart Study (FHS, Genetic Analysis Work-
shop 16 Problem 2) to compare the influence of control
selection on the results for T2D.
Methods
FHS
The FHS is a community-based, multigenerational,
longitudinal study of cardiovascular disease and its risk
factors, including diabetes. The FHS began in 1948 to
investigate the causes of heart disease. Men and women
between the ages of 28 and 62 years were recruited and
followed prospectively over time. Beginning in 1971,
offspring of the Original Cohort were recruited as part of
the Framingham Offspring Study. There are a total of
6752 subjects. There are 765 pedigrees with 2 to 301
genotyped subjects: 134 pedigrees with 2, 123 with 3, 98
with 4, 85 with 5, 177 with 6 to 10, 72 with 11 to 15, 30
with 16 to 20, and 46 with more than 20.
Genotyping
FHS GWAS data were generated on the Affymetrix 250 k
Sty, 250 k Nsp, and the supplemental 50 k platforms.
Single-nucleotide polymorphisms (SNPs) were selected
for analyses were based on previously reported GWAS
[3,4]. The genes and SNPs used in this study to represent
the 18 most significant T2D SNPs from these GWAS are:
peroxisome proliferator-activated receptor gamma
(PPARG; rs1801282); insulin-like growth factor two
binding protein 2 (IGF2BP2; rs4402960); cyclin-depen-
dent kinase 5, a regulatory subunit-associated protein1-
like 1 (CDKAL1; rs7754840 and rs10946398); a variant
found near cyclin-dependent kinase inhibitor 2A/2B
(CDKN2A/2B; rs10811661 and rs564398); hematopoie-
tically expressed homeobox (HHEX; rs5015480 (r
2 =1
with rs1111875); transcription factor-7-like 2 (TCF7L2;
rs10885409 and rs7901695 (r
2 = 0.8 with rs7903146));
potassium inwardly rectifying channel subfamily J
member 11(KCNJ11;r s 5 2 1 5( r
2 = 0.89 with rs5219));
fat mass obesity-associated gene (FTO; rs9939609 and
rs8050136); tetraspanin 8/leucine-rich repeat-containing
G protein-coupled receptor 5 (TSPAN8/LGR5;
rs7961581); cell division cycle 123 (CDC123;
rs4747969 (r
2 = 0.83 with rs12779790)); Wolfram
syndrome 1 (WFS1; rs4689394 (r
2 =1w i t h
rs10010131)); ADAM metallopeptidase with thrombos-
pondin type 1 motif, 9 (ADAMTS9; rs4607103); thyroid
adenoma associated (THADA; rs13431070 (r
2 =1w i t h
rs7578597); and JAZF zinc finger 1 (JAZF1; rs864745).
Case-control definitions
Cases were defined as people with a diagnosis of type 2
diabetes (T2D) during follow-up of the FHS cohort.
Cases were born during the first, the second, or the
third generation of the FHS. The age at diagnosis
for 231 unrelated male and female cases was 20 to
80 years old.
In our nested incidence density case-control approach,
10 individually matched controls were selected with
replacement from members of the cohort who did not
have a T2D diagnosis at the time when the case was
identified. Age is a strong risk factor for T2D disease, and
so controls were always selected among participants of
the same age at enrollment as the cases ( ± 5 years).
Controls were additionally matched on sex and body
m a s si n d e x( B M I )a te n r o l l m e n t(±2k g / m
2). For every
case, ten randomly chosen controls were selected by
incidence density sampling. Cases and controls were not
members of the same family. In our case-exclusion
approach, controls were selected as members of the FHS
who never received a T2D diagnosis during any of the
recorded follow-up. We then adjusted for age, sex, and
BMI matching criteria as in our nested case-control
approach.
Statistical analyses
As a quality control measure, we tested for Hardy-
Weinberg disequilibrium in controls using an exact test.
All markers are in Hardy-Weinberg equilibrium in the
observed FHS data and in all simulated samples. All
individuals had complete data for sex, age, BMI, and
diabetes except 15 controls in the incidence density (ID)
sample and 28 in the case exclusion (CE) sample for
whom BMI at enrollment was not available. All SNPs
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to be acceptable.
Genetic associations with T2D (odds ratios, confidence
intervals, and statistical tests) were estimated and tested
using a conditional logistic regression under the additive
model for the ID sampling approach and using logistic
regression, adjusted for matching variables, in the case-
exclusion approach. These analyses were carried out in
SAS software using the PHREG procedure.
Simulations
Simulations were used to investigate control selection
effects in a larger sample of individuals than that in the
observed FHS data, and with SNPs having higher effect
sizes. We simulated 11 sets of 100 replicates according
to varying minor allele frequencies and generating
hazard ratios. These simulations were used to estimate
bias and power between the control sampling designs. A
S A Sp r o g r a mw a su s e dt os i m u l a t ed i a b e t e sa sa
function of SNP genotype. We generated data sets of
10,000 individuals with SNP genotypes assigned prob-
abilistically according to allele frequencies of 0.10, 0.30,
or 0.50. We then assigned diabetes status and time of
onset using an exponential model based on SNP hazard
ratios from 1.3 to 3 (see Table 1). We selected five
controls for each case according to the ID (risk set)
sampling scheme and set a 5:1 control:case ratio for the
CE sampling at end of follow up. We then estimated
odds ratios (ORs), confidence intervals (CIs) and
performed tests of association for each SNP. We
repeated this 100 times to report average bias and
estimated power for each SNP (defined as the propor-
tion with statistically significant association (p < 0.05)).
Bias ratios between ID and CE methods were estimated
by the ratio “calculated OR per method/generating
hazard ratio in simulations”.
Results and discussion
In order to maximize precision, we chose a ratio of 10
controls per case for both sampling strategies in the FHS
data. Because we did not have exact dates and BMI at
onset of diabetes, we used the age at enrollment, i.e., the
age at Visit 1, and BMI at enrollment to match cases and
controls. To accommodate the effect of random ID
control selection, we repeated random sampling and
conditional logistic regression 10 times. The distribution
of OR estimates obtained in each analysis showed wide
variability across replicates, with a coefficient of varia-
tion from 14% to 20% per SNP among the ID sampling
replicates. We report the average OR from these 10
replicates in Table 2, along with confidence limits based
on the method of Rubin [5] that takes within-replicate
and across-replicate variation into account. We also
show the average p-value per SNP to indicate whether
statistical significance was achieved in any replicate.
We failed to find any significant association with any of
the 18 previously reported SNPs using ID sampling or
CE sampling in FHS (Table 2). We included 18 SNPs
with convincing association evidence; however, two
important SNPs were missing in our genotyping data
(rs757210 in TCF2 and rs13266634 in SLC30A8), and
could not be considered in the FHS. One drawback of
our study is the limited number of T2D cases, despite the
very large database. With only 189 incident cases and
231 total cases, our study had low power to detect
genetic association between SNPs and T2D, especially
considering the expected magnitudes of association
based on previous reports. Owing to the large CIs of
the ORs in our two scenarios, the results would have
been less conclusive than those of the previous studies
conducted in larger sample (>1000 cases). An alternative
explanation for the low power is that we considered each
SNP separately rather than a combination of variants
acting additively on risk, which may have a large effect.
Table 1: OR and bias from simulated cohorts under different control sampling designs based on 100 replicates for each design
Generated hazard ratio ID sampling CE sampling
SNP OR MAF OR (CI)
a Bias ratio Power OR (CI) Bias ratio Power
Gene1.3_0.1 1.3 0.1 1.29 (0.83-1.99) 0.99 0.43 1.38 (0.86-2.18) 1.06 0.66
Gene1.3_0.3 1.3 0.3 1.30 (0.79-1.26) 1.00 0.97 1.37 (0.77-1.29) 1.04 0.98
Gene1.3_0.5 1.3 0.5 1.29 (0.80-1.25) 0.99 0.96 1.36 (0.78-1.29) 1.04 0.99
Gene1.5_0.1 1.5 0.1 1.57 (0.49-2.05) 1.04 0.92 1.59 (0.52-1.90) 1.06 0.91
Gene1.5_0.3 1.5 0.3 1.54 (0.58-1.72) 1.02 1.00 1.61 (0.59-1.71) 1.08 1.00
Gene1.5_0.5 1.5 0.5 1.55 (0.55-1.82) 1.03 1.00 1.62 (0.57-1.76) 1.09 1.00
Gene1.8_0.1 1.8 0.1 1.90 (0.27-3.47) 1.06 1.00 2.03 (0.24-4.18) 1.13 1.00
Gene1.8_0.3 1.8 0.3 1.75 (0.38-2.64) 0.97 1.00 1.96 (0.30-3.31) 1.09 1.00
Gene1.8_0.5 1.8 0.5 1.77 (0.36-2.80) 0.99 1.00 1.97 (0.29-3.47) 1.09 1.00
Gene2_0.5 2.0 0.5 1.78 (0.52-2.08) 0.89 1.00 2.64 (0.25-3.10) 1.32 1.00
Gene3_0.5 3.0 0.5 2.92 (0.47-3.44) 0.97 1.00 3.67 (0.38-4.34) 1.22 1.00
aCI, 95% confidence interval.
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the small number of cases and small effect sizes, we
further addressed differences between control sampling
methods via simulation with higher sample sizes and
effect sizes. For each simulating scenario, we simulated
100 cohort data sets, each with approximately 500 cases,
as described in the Methods section (Table 1). These
simulations show that when more precision can be
obtained and higher effect sizes are considered, ID
sampling does indeed have less bias, while CE methods
have a slight upward bias, leading to the appearance of
increase power. We suggest that this increased power
should be considered with caution given the bias, and
recommend ID sampling as the appropriate strategy for
case-control analyses nested in cohorts.
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Table 2: OR for T2D SNPs from previous meta-analysis and in the FHS data under different control sampling designs
Previous studies ID sampling CE sampling
SNP OR (CI) MAF OR (CI)
a OR (CI)
rs4607103 1.09 (1.06-1.12) 0.20 1.26 (0.56-2.83) 1.28 (0.71-2.35)
rs4747969 1.11 (1.07-1.14) 0.27 1.21 (0.53-2.74) 1.21 (0.63-2.29)
rs10946398 1.14 (1.11-1.17) 0.31 1.26 (0.85-1.86) 1.24 (0.73-2.09)
rs7754840 1.12 (1.08-1.16) 0.31 1.24 (0.84-1.85) 1.30 (0.75-2.27)
rs10811661 1.20 (1.14-1.25) 0.21 1.32 (0.66-2.63) 1.14 (0.57-2.28)
rs564398 1.12 (1.07-1.17) 0.37 0.91 (0.63-1.31) 1.21 (0.73-2.01)
rs8050136 1.17 (1.12-1.22) 0.45 1.05 (0.73-1.48) 1.69 (1.05-2.72)
rs9939609 1.11 (1.02-1.20) 0.45 1.16 (0.74-1.47) 1.69 (1.06-2.73)
rs5015480 1.15 (1.10-1.19) 0.43 1.25 (0.81-1.93) 1.21 (0.72-2.03)
rs4402960 1.14 (1.11-1.18) 0.29 1.01 (0.68-1.50) 1.02 (0.61-1.70)
rs864745 1.10 (1.07-1.13) 0.48 1.24 (0.80-1.91) 1.38 (0.83-2.29)
rs5215 1.14 (1.10-1.19) 0.41 1.14 (0.70-1.84) 1.03 (0.62-1.70)
rs1801282 1.14 (1.08-1.20) 0.07 1.02 (0.61-1.69) 1.01 (0.45-2.93)
rs10885409 1.29 (1.07-1.54) 0.42 1.25 (0.81-1.92) 1.50 (0.77-2.93)
rs7901695 1.37 (1.31-1.43) 0.28 1.34 (0.85-2.09) 1.07 (0.53-2.16)
rs13431070 1.15 (1.10-1.20) 0.08 1.33 (0.58-3.05) 1.02 (0.46-2.29)
rs7961581 1.09 (1.06-1.12) 0.23 1.16 (0.84-1.61) 1.03 (0.60-1.75)
rs4689394 1.11 (1.08-1.16) 0.27 1.18 (0.71-1.95) 1.23 (0.74-2.04)
aAverage OR and CI (95% confidence interval) across 10 replicates.
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